BACKGROUND Trimetazidine is an anti-ischemic agent with cardioprotective effects. The purpose of this double-blind, controlled, prospective randomized study was to investigate the possible effects of the preoperative use of trimetazidine on the biochemical markers of myocardial injury during open heart surgery and to determine if it has any myocardial protective effects. METHODS Thirty patien...

This review summarizes the available evidence on the cardioprotective effects of trimetazidine, focusing on clinical studies in a large spectrum of patients, including those with stable angina pectoris, acute myocardial infarction, ischemic cardiomyopathy, heart failure, and those undergoing percutaneous coronary intervention. The cardioprotective effects of trimetazidine have been proven both ...

Antiarrhythmic effects of intravenous coronary vasodilators (verapamil, diltiazem, bepridil, trimetazidine and nicorandil) were evaluated using two canine ventricular arrhythmia models (halothane-adrenaline arrhythmia and digitalis arrhythmia), and the minimum effective plasma concentrations of the drugs were determined for each arrhythmia model. Verapamil (0.1 mg/kg), diltiazem (0.1 mg/kg), be...

A rapid liquid chromatography electrospray ionization mass spectrometry (LC/ESI-MS) method with good sensitivity and specificity has been developed and validated for the identification and quantification of trimetazidine in human plasma. Trimetazidine and lidocaine (internal standard) were isolated from plasma samples by protein precipitation with methanol. The chromatographic separation was ac...

OBJECTIVE To assess antianginal efficacy and possible adverse haemodynamic effects of combination treatment with trimetazidine and diltiazem in patients with stable angina. DESIGN Double blind, randomised, placebo controlled trial of four weeks duration. SETTING Outpatient department of two Indian hospitals. SUBJECTS 64 male patients with stable angina, uncontrolled on diltiazem alone. ...

The available studies provide an apparent compilation of diverse and solid research evidence on the possible nephroprotective role of trimetazidine. However, large, randomized, placebo-controlled, preferably multicentre studies are necessary to confirm this hypothesis in non-dialyzed, chronic renal failure and haemodialyzed patients. The extent of the challenge would also be related to specific...

BACKGROUND Trimetazidine is an anti-ischemic agent with anti-oxidant activity. This study sought to evaluate the impact of oral trimetazidine on extent of myocardial damage in diabetic patients who were presented with anterior wall ST-segment elevation myocardial infarction (STEMI). METHODS One hundred patients were prospectively enrolled, and then randomly assigned to receive oral trimetazid...

BACKGROUND Trimetazidine is an anti-ischemic agent that is used to treat angina and it has cardioprotective effects without inducing any significant hemodynamic changes. It inhibits the long-chain mitochondrial 3-ketoacyl coenzyme A thiolase enzyme in the myocyte and can improve cardiac mitochondrial metabolism, as well as scavenge free radicals. The aim of this double-blind prospective randomi...

Ischemia-reperfusion syndrome is defined as myocardial injury caused by the restoration of coronary flow. This phenomenon has a complex pathophysiology and results in a paradoxical reduction of the beneficial effect of myocardial reperfusion. Studies suggest that ischemia-reperfusion injury may account for up to 50% of the final size of a myocardial infarct. Vastarel MR (trimetazidine) is a pha...

A direct approach to manipulating cardiac energy metabolism consists of modifying substrate utilization by the heart. Pharmacological agents that directly inhibit fatty acid oxidation include inhibitors of 3-ketoacyl coenzyme A thiolase, the last enzyme involved in b-oxidation. The most extensively investigated agent of this group of drugs is trimetazidine. Clinical studies have shown that trim...